bupropion [smoking] (ZYBAN)

Drug and Dietary Supplement Profiles

A comprehensive review of the safety and effectiveness of this drug. If the drug is not a Do Not Use product, information on adverse effects, drug interactions and how to use the medication are included.

Search results below include drug profiles where your selected drug is a primary subject of discussion

Disease and Drug Family Information

Search results below include Disease and Drug Family Information where your selected drug is a primary subject of discussion

Smoking Cessation [hide all summaries]
There is no question that smoking involves a physical addiction to nicotine as well as psychological addiction to the patterns of smoking in certain circumstances or situations. Unless attention is paid to both of these kinds of addiction, the chance of success in stopping smoking will not be as good as it could be.

Worst Pills, Best Pills Newsletter Articles

Search results below include Worst Pills, Best Pills Newsletter Articles where your selected drug is a primary subject of discussion

A Review of Varenicline (CHANTIX) To Quit Smoking [hide all summaries]
(September 2007)
Varenicline was approved by the FDA in May 2006 for use as an aid in smoking cessation treatment. It belongs to a new family of drugs, not containing nicotine, but thought to work by stimulating nicotine receptors in the brain, just as nicotine does.

FDA: All Antidepressants Should Carry Warnings About Risks of Suicidal Thoughts in Young Adults [hide all summaries]
(July 2007)
Because of new information about increased risks of suicidal thoughts associated with the use of a variety of antidepressants, people of all ages should be monitored closely with all antidepressants after the drugs are first prescribed, switched or when the dosage is changed. Do not stop using any antidepressants without first consulting the prescriber.

Black Box Warning To Be Required On All Antidepressants Concerning Suicide Risk In Children And Adolescents [hide all summaries]
(December 2004)
Belatedly, the Food and Drug Administration (FDA) announced on October 15, 2004 that it is taking steps to inform parents and physicians about the risks of antidepressants when these drugs are used to treat major depressive disorder in children and adolescents.

Canadians Warned of Potential Adverse Effects of Maternal Use of Antidepressants on Newborns. American Mothers Still in the Dark [hide all summaries]
(October 2004)
The Canadian equivalent of the Food and Drug Administration (FDA), Health Canada, issued a public advisory on August 9, 2004 warning that newborns may be adversely affected when their mothers take one of the family of antidepressants known as selective serotonin reuptake inhibitors (SSRIs) and other newer anti-depressants during the third trimester of pregnancy.